Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients.
about
Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog TherapyKASL clinical practice guidelines: management of chronic hepatitis BManagement of chronic hepatitis B infection: current treatment guidelines, challenges, and new developmentsAlpha-interferon treatment in hepatitis BChronic hepatitis B: Advances in treatment.Comparison of three luminescent immunoassays for hepatitis B virus surface antigen quantification during the natural history of chronic hepatitis B virus infection.Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy?Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis.Improved Efficacy of a pegylated interferon-α-2a stepwise optimization treatment strategy in the treatment of hepatitis B e antigen-positive chronic hepatitis B patients.Elecsys hepatitis B surface antigen quantitative assay: performance evaluation and correlation with hepatitis B virus DNA during 96 weeks of follow-up in chronic hepatitis B patients.Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2aVirus and Host Testing to Manage Chronic Hepatitis B.Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysisHBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patientsSASLT practice guidelines for the management of hepatitis B virus.Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.Clinical implications of HBsAg quantification in patients with chronic hepatitis B.Expert recommendations on the application of interferon for chronic hepatitis B.HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.Monotherapy for hepatitis B infection: a review of treatment options.Virological and serological tools to optimize the management of patients with chronic hepatitis B.An update on the strategies used for the treatment of chronic hepatitis B in children.The Efficacy and Safety of Peginterferon-α-2a in Korean Patients with Chronic Hepatitis B: A Multicenter Study Conducted in a Real Clinical Setting.Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study.Hepatitis B surface antigen reduction by switching from long-term nucleoside/nucleotide analogue administration to pegylated interferon.Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B.HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy.Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline.JSH Guidelines for the Management of Hepatitis B Virus Infection.Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs.Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.Plasmacytoid Dendritic Cell Function and Cytokine Network Profiles in Patients with Acute or Chronic Hepatitis B Virus Infection.Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B.
P2860
Q26740161-D2192965-F455-4926-B8A2-043EDDC4C799Q26752475-5B07C7A8-3159-4E49-AAC1-D49918A4ED06Q27008984-20539B15-BE34-4DF0-93A3-666E383F701DQ33592755-7781C846-C3EE-4E94-8C32-D72141BBDBDEQ33660010-FD0DDB9F-D088-41A6-9DDD-20C1BDEC78A7Q34592952-E27328F6-C33E-4D62-B3B8-2C2C0F6EC008Q34674838-356F6D58-2D19-4F13-A199-2A9223F475B7Q35118955-A18F43F1-720E-4359-A167-83EEA9373BC4Q35250340-C96C3BB2-6A6E-444B-A177-041D7EC5F928Q35688409-597E721F-12F2-4452-AEFE-CA1CE4C9507DQ36153775-E091FD3B-B13F-4431-82EB-7337E82DE2C2Q36365030-2FAE3CE4-B1E1-4033-8DA6-512BC9BEA06CQ36924978-183CC952-6BF2-4906-B19C-3E964FA3A0F0Q36958940-B379D801-5B16-45C0-8511-608346A63975Q36973383-5A46808D-5CCE-4C80-8517-519D15669E90Q37087279-450961E5-3904-4832-A967-8D48BD58A81BQ37374481-08193CFE-36FC-48CB-A84F-02174A95DBBEQ37634822-4B30E959-B361-4BCE-BD73-CC05B2BD6970Q37684139-6B191284-F069-47A8-A91B-04F9AA2A7B8CQ37994049-57730B82-22EB-4566-B53E-D9DF70DAA5B8Q38131868-D536DA19-94C5-4437-B13F-D5E1AC2881D0Q38295840-F68DF8FB-718D-4EBE-85A6-C6920111E93BQ38594605-03C34318-32FC-4452-808D-220AE6B5B6BEQ38685589-0C24420B-A917-44C4-86B7-D6331E0D9A40Q38692198-36199928-5446-4406-B5AB-BBC6F8D68C58Q39284357-526EA23B-F276-4F62-86F0-D0B414434E81Q39388862-7EEDF723-B6E6-4C51-9031-38BE07BE8CF7Q39903061-01EE2126-E65C-4D90-8207-DC4F816A046EQ40335324-602F093D-F193-4574-B380-0F0F7C9F8A3AQ40716013-0B184D70-E219-4A5F-A109-60EB8EB069F6Q41042019-F3598AC0-58F6-4357-B61D-EC4F2417CEAAQ41718138-474ABFBF-ED37-47CF-9476-A07D76737329Q42242300-8F31EB9E-EA2F-48E5-8800-518A8C8898BEQ42244740-6B499EC4-50D5-4E70-8243-B7BB6D28249FQ42683825-82B55652-646E-451A-A3AA-BD3A8569C946Q45324582-0C7A5288-D6A7-45C9-AD7C-631B959CF42FQ47561347-D25D9C30-5E30-4281-A73A-647D14478F87Q52632461-B351CB6F-9984-41D4-97E6-36B7DEE55BCE
P2860
Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Hepatitis B surface antigen: a ...... B e antigen-positive patients.
@en
Hepatitis B surface antigen: a ...... B e antigen-positive patients.
@nl
type
label
Hepatitis B surface antigen: a ...... B e antigen-positive patients.
@en
Hepatitis B surface antigen: a ...... B e antigen-positive patients.
@nl
prefLabel
Hepatitis B surface antigen: a ...... B e antigen-positive patients.
@en
Hepatitis B surface antigen: a ...... B e antigen-positive patients.
@nl
P2093
P2860
P1476
Hepatitis B surface antigen: a ...... B e antigen-positive patients.
@en
P2093
Hans-Peter Kapprell
Matei Popescu
Patrick Marcellin
Teerha Piratvisuth
Vivien Rothe
Zhi-Meng Lu
P2860
P2888
P304
P356
10.1007/S12072-011-9280-0
P577
2011-06-24T00:00:00Z